Monthly ibandronate suppresses serum CTX-I within 3 days and maintains a monthly fluctuating pattern of suppression

Osteoporosis International

Volumn 20, Issue 9, 2009, Pages 1595-1601

  Binkley, N ^a   Silverman, S L ^b   Simonelli, C ^c   Santiago, N ^d   Kohles, J D ^e   Dasic, G ^f   Sunyecz, J A ^g  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Health East Osteoporosis Care   (United States)

^d Ponce Gastroenterology Research   (Puerto Rico)

^e HOFFMANN LA ROCHE INC   (United States)

^f GLAXOSMITHKLINE   (United States)

^g Laurel Highlands Ob/Gyn   (United States)

Author keywords

Bisphosphonates; Bone turnover markers; Ibandronate; Postmenopausal osteoporosis

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; C TERMINAL CROSS LINKING TELOPEPTIDE OF TYPE I COLLAGEN; CALCIUM CARBONATE; COLECALCIFEROL; COLLAGEN DERIVATIVE; IBANDRONIC ACID; PLACEBO; UNCLASSIFIED DRUG;

ACUTE DISEASE; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FRACTURE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MORNING DOSAGE; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; TREATMENT DURATION;

BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; BONE RESORPTION; COLLAGEN TYPE I; DIPHOSPHONATES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDES; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 68949209968     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-008-0827-4     Document Type: Article

References (24)

1. SC Manolagas 2000 Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis Endocr Rev 21 115 137
2. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy 2001 Osteoporosis prevention, diagnosis, and therapy JAMA 285 785 795
3. AK Srivastava EL Vliet EM Lewiecki, et al 2005 Clinical use of serum and urine bone markers in the management of osteoporosis Curr Med Res Opin 21 1015 1026
4. M Gass R Kagan J Kohles, et al 2008 Bone turnover marker profile in relation to the menstrual cycle of premenopausal healthy women Menopause 15 667 675
5. AI Sebba S Broy JD Kohles, et al 2008 Rapid suppression of bone resorption marker levels with ibandronate therapy in a bisphosphonate-naive population J Clin Densitom 11 417 423
6. K Saag R Lindsay A Kriegman, et al 2007 A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density Bone 40 1238 1243
7. DC Bauer DM Black P Garnero, et al 2004 Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial J Bone Miner Res 19 1250 1258
8. DJ Leeming P Alexandersen MA Karsdal, et al 2006 An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice Eur J Clin Pharmacol 62 781 792
9. RR Recker R Gallagher PE MacCosbe 2005 Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women Mayo Clin Proc 80 856 861
10. JA Cramer MM Amonkar A Hebborn, et al 2005 Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis Curr Med Res Opin 21 1453 1460
11. PD Delmas B Vrijens R Eastell, et al 2007 Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis J Clin Endocrinol Metab 92 1296 1304
12. CH Chesnut MP Ettinger PD Miller, et al 2005 Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE Curr Med Res Opin 21 391 401
13. JY Reginster S Adami P Lakatos, et al 2006 Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study Ann Rheum Dis 65 654 661
14. S Bonnick KG Saag DP Kiel, et al 2006 Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years J Clin Endocrinol Metab 91 2631 2637
15. L Raisz JA Smith M Trahiotis, et al 2000 Short-term risedronate treatment in postmenopausal women: effects on biochemical markers of bone turnover Osteoporos Int 11 615 620
16. National Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis. Available at http://www.nof.org/physguide/ pharmacologic.htm. Accessed August 7, 2007
17. Serum CrossLaps® ELISA package insert. Nordic Bioscience Diagnostics A/S, Herlev, Denmark
18. Quidel Metra BAP EIA Kit, package insert. Quidel, San Diego, CA
19. ES Siris ST Harris CJ Rosen, et al 2006 Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases Mayo Clin Proc 81 1013 1022
20. EM Lewiecki 2003 Nonresponders to osteoporosis study J Clin Densitom 6 307 314
21. P Ravn B Clemmesen C Christiansen 1999 Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group Bone 24 237 244
22. N Binkley JP Bilezikian DL Kendler, et al 2006 Official positions of the International Society for Clinical Densitometry and Executive Summary of the 2005 Position Development Conference J Clin Densitom 9 4 14
23. PD Miller 2007 Monitoring osteoporosis therapies Curr Osteoporos Rep 5 38 43
24. JA Clowes NF Peel R Eastell 2004 The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial J Clin Endocrinol Metab 89 1117 1123